What is Cue Biopharma's market cap?

Cue Biopharma (CUE) has a market capitalization of $155.8M and trades on NASDAQ.

Who are Cue Biopharma's competitors?

Cue Biopharma's key competitors include Coya Therapeutics, Nektar Therapeutics, Cullinan Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Cue Biopharma partner with?

Cue Biopharma's notable partners include Boehringer Ingelheim International GmbH, ImmunoScape Pte. Ltd., Albert Einstein College of Medicine, and others.

Where is Cue Biopharma headquartered?

Cue Biopharma is headquartered in United States of America and employs approximately 53 people. It has been publicly traded since 2018.

Cue Biopharma (CUE) Stock Fundamentals & Financials

Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics designed to selectively modulate disease-specific T cells.

Market cap

$155.82M+177%

Earnings

Q2 2026 report

August 14, 2026

Revenue$7.9MBeat by $4.9M EPS-$24.14Miss by $22.45

Read the full report

Next report

Nov 11, 2026 (In 1 week)

Revenue estimate$1.0M

EPS estimate-$2.24

Competitors

By market cap

Merck & Co.$361.02B+67.5%

Amgen$249.09B+58.4%

Bristol-Myers Squibb$125.49B+35.1%

Nektar Therapeutics$1.3B+12.0%

Cullinan Therapeutics, Inc.$994.3M+123%

Climb Bio, Inc.$593.3M+340%

Cue Biopharma$155.8M+190%

Coya Therapeutics, Inc.$93.4M-27.1%

By revenue growth

Amgen+9.1%

Merck & Co.+4.9%

Bristol-Myers Squibb+4.2%

Nektar Therapeutics-27.2%

By net margin

Amgen22.95%+4.0pp

Bristol-Myers Squibb18.47%+6.0pp

Merck & Co.4.77%—

Nektar Therapeutics-287.84%-115pp

Cullinan Therapeutics, Inc.-346.14%—

Profile

Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics designed to selectively modulate disease-specific T cells. Utilizing its proprietary Immuno-STAT platform, the company engineers biologics that aim to restore immune balance in autoimmune and inflammatory diseases while minimizing off-target effects. The company's strategy involves leveraging this modular framework to establish new standards of care through internal development and strategic pharmaceutical collaborations.

Competitive position

A clinical-stage innovator utilizing a differentiated, modular platform (Immuno-STAT) to provide targeted T cell modulation as an alternative to broad immune activation.

GeographiesUnited States, Global

Customer segmentsPharmaceutical Companies, Biotechnology Companies

Business modelResearch and Development, IP Licensing, Strategic Collaboration

SuppliersAcademic research institutions, Contract manufacturing organizations, Specialized laboratory equipment providers, Patent licensors

CustomersGlobal pharmaceutical companies, Clinical trial participants, Specialized oncology and immunology clinics

CountryUnited States of America

Listed2018

Employees53.0

CEOShao-Lee Lin

SectorHealthcare

IndustryBiotechnology

Websitecuebiopharma.com

FilingsSEC EDGAR

FAQ

What is Cue Biopharma's market cap?: Cue Biopharma (CUE) has a market capitalization of $155.8M and trades on NASDAQ.
Who are Cue Biopharma's competitors?: Cue Biopharma's key competitors include Coya Therapeutics, Nektar Therapeutics, Cullinan Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Cue Biopharma partner with?: Cue Biopharma's notable partners include Boehringer Ingelheim International GmbH, ImmunoScape Pte. Ltd., Albert Einstein College of Medicine, and others.
Where is Cue Biopharma headquartered?: Cue Biopharma is headquartered in United States of America and employs approximately 53 people. It has been publicly traded since 2018.